By: IPP Bureau
Last updated : July 10, 2022 1:19 pm
Dr. Reddy's Fesoterodine Fumarate Extended-Release Tablets are available in 4 mg and 8 mg Tablets, each in bottle count sizes of 30.
Dr. Reddy's Labs launches Fesoterodine Fumarate Extended-Release Tablets in the U.S. market
Dr. Reddy's Laboratories, along with its subsidiaries announces the launch of Dr. Reddy's Fesoterodine Fumarate Extended-Release Tablets, a therapeutic generic equivalent to Toviaz (fesoterodine fumarate) Extended-Release Tablets in the U.S. market following the approval by the U.S. Food and Drug Administration (USFDA).
The Toviaz brand had U.S. sales of approximately $211 million MAT for the most recent twelve months ending in May 2022 according to IQVIA.
Dr. Reddy's Fesoterodine Fumarate Extended-Release Tablets are available in 4 mg and 8 mg Tablets, each in bottle count sizes of 30.